Filtrer vos résultats
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA RegistryEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2022, ⟨10.1093/ehjcvp/pvac028⟩
Article dans une revue
hal-03675513v1
|